ReviewBrain sciences2022
The Effect of Menopause on Antipsychotic Response.
Review in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia.CNS drugs · 2024Trial
- Olanzapine Dosing in Women with First-Episode Psychosis: An Age-Based Proxy for Menopausal Status.Schizophrenia bulletin · 2026Article
- Pharmacological Management of ADHD in Women Across Perimenopause, Menopause and Post-Menopause.Drugs & aging · 2026Review
- Considerations and practical recommendations for identifying perimenopause in longitudinal research.Psychoneuroendocrinology · 2026Review
- Trajectories of Clozapine Concentrations in Women Across Menopausal Age.Schizophrenia bulletin · 2026Article
- Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study.Frontiers in pharmacology · 2026Article
- The effect of age on the clinical presentation and treatment of women with psychosis: secondary analysis of the IMPaCT Randomised Clinical Trial.BJPsych open · 2025Article
- Reproductive and Fertility Care of Women with Schizophrenia: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- 17β-estradiol status alters NMDAR function and antipsychotic-like activity in female rats.Molecular psychiatry · 2025Article
- Age and sex differences in outpatient antipsychotic prescriptions for schizophrenia: a claims data study.European archives of psychiatry and clinical neuroscience · 2025Article
- Optimizing perimenopausal mental health by integrating precision biomarkers, digital health interventions, and psychosocial care.World journal of psychiatry · 2025Article
- Knowledge, attitude, and practice toward sleep disorders and sleep hygiene among perimenopausal women.Scientific reports · 2024Article
- Long-acting antipsychotic treatments: focus on women with schizophrenia.Therapeutic advances in psychopharmacology · 2024Review
- Paliperidone long-acting injection in the treatment of an adolescent with schizophrenia with fluctuating mental symptoms during menstrual period: a case report.Frontiers in psychiatry · 2023Article
- Schizophrenia and dementia across the lifespan: epidemiological links, cognitive trajectories, and the pathophysiological interplay.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It has been hypothesized that, whenever estrogen levels decline, psychosis symptoms in women increase. At menopause, this can happen in two main ways: (a) the loss of estrogen (mainly estradiol) can directly affect central neurotransmission, leading to increase in schizophrenia-related symptoms, and (b) the loss of estrogen can decrease the synthesis of enzymes that metabolize antipsychotic drugs, thus weakening their efficacy. Aims and Methods: The aim of this narrative review was to investigate the second possibility by searching PubMed and ClinicalTrials.gov for studies over the last two decades that investigated the metabolism of antipsychotics and their efficacy before and after menopause in women or that studied systemic and local estrogen level effects on the pharmacokinetics and pharmacodynamics of individual antipsychotic drugs. Results: The evidence suggests that symptom level in women with schizophrenia rises after menopause for many reasons beyond hormones but, importantly, there is an estrogen-dependent loss of efficacy related to antipsychotic treatment. Conclusion: Effective clinical intervention is challenging; nevertheless, several promising routes forward are suggested.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.